Drug discovery

#Biology #Drug discovery #IBD

Galapagos advances IBD targets discovered using Scipher platform

Biotechnology company Galapagos will in-license drug targets for inflammatory bowel disease (IBD) which were discovered using a biology platform developed by Scipher Medicine. The move follows a deal Galapagos and Scipher Medicine made in 2020 to jointly validate a suite of novel IBD targets discovered by Scipher’s Spectra platform. Under… Read More

#News

#AI / data analytics / healthtech / informatics #DEL #Drug discovery

AI in action: examples of AI across drug discovery

Drug discovery and development is a challenging multiparameter optimisation problem. Harnessing the power of artificial intelligence (AI) can help accurately predict the behaviour and properties of small molecules. In this on-demand webinar from X-Chem you will see: How AI and DNA-encoded library (DEL) screening are transforming early phase drug… Read More

#News

#CRISPR #CRISPR screening #CRISPR-Cas9 #Drug discovery

CRISPR-Cas9 screening: webinar

Join DDW, supported by Horizon Discovery for this exclusive free event which will examine CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event will take place on 9 June 2022, 3PM BST. Register for free here. Joanna… Read More

#News

#AI #Drug development #Drug discovery

Iktos teams up with Sygnature Discovery on development project  

Artificial intelligence company Iktos has announced a collaboration with drug discovery company Sygnature Discovery in a deal designed to accelerate drug discovery and development.  The three-year deal will see Sygnature using Iktos’ de novogenerative design software Makya to facilitate rapid and efficient design of novel… Read More

#News

#AI #Data #Drug discovery

BenevolentAI achieves third milestone with AstraZeneca

AstraZeneca has identified an additional target for its idiopathic pulmonary fibrosis (IPF) pipeline using an AI system designed by drug discovery company BenevolentAI. It is now the third target from that collaboration that has been identified using BenevolentAI’s platform. AstraZeneca is using the company’s Benevolent Platform across two disease areas… Read More

#News

#Covid-19 #Drug discovery #Genetics

Biotechs partner to understand genetics of long Covid   

A partnership between life sciences companies PrecisionLife and Sano Genetics aims to drive insights into the genetics of long Covid and potentially identify new treatments.    The companies will analyse Sano Genetics’ data of 3,000 adults suffering from long Covid symptoms using PrecisionLife’s combinatorial analytics platform… Read More

#Covid-19 #News

#CRISPR #CRISPR screening #CRISPR-Cas9 #Drug discovery

CRISPR-Cas9 screening: a powerful approach to drug discovery

Join DDW, supported by Horizon Discovery for this exclusive free event which will examine CRISPR-Cas9 screening and how it offers a powerful approach to advancing drug discovery and the understanding of genetic disease. The event will take place on 9 June 2022, 3PM BST. Register for free here. Joanna… Read More

#News

#Clinical research #Drug development #Drug discovery #Supply chain

Achieving faster drug lifecycle management 

Eugene Polini, Technical Key Account Manager at Datwyler examines the challenges drug developers are facing to speed up production lifecycles and what solutions are available to them.  While people around the world hope to never see another global pandemic in their lifetimes, it is the responsibility of pharmaceutical manufacturers to… Read More

#News

#AI #Drug discovery

DNDi and BenevolentAI to tackle dengue in drug discovery project  

Artificial intelligence (AI) company BenevolentAI and not-for-profit R&D organisation Drugs for Neglected Disease initiative (DNDi) have launched a joint research project to tackle dengue, one of the world’s most prevalent infectious diseases.  Dengue represents one of the top 10 threats to global public health worldwide. Despite an… Read More

#News

#AI #Drug discovery #Small molecules

X-Chem launches small molecule discovery platform

Artificial intelligence (AI) company X-Chem has announced that its drug discovery platform XD3 is now available to biopharma partners and clients. XD3 is the company’s small molecule drug discovery platform and combines data generated through DNA-encoded library (DEL) screening, along with analytical and predictive capabilities offered by A-Chem’s AI platform,… Read More

#News

#Assays #Biopharmaceuticals #Biotherapeutics #Drug development #Drug discovery

PerkinElmer releases assay kits for more effective biotherapeutics 

PerkinElmer has announced two ready-to-use HTRF and AlphaLISA no-wash assay kits designed to quickly and easily detect and quantify CHO HCP impurities during biopharmaceutical manufacturing.   Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines and other biologics, must be free of residual host cell protein (HCP) impurities… Read More

#News

#AI #Business Intelligence Group #Drug discovery

X-Chem VP recognised for AI contributions  

Noor Shaker, the Senior Vice President and General Manager for DNA technology company X-Chem, has been named a winner in the Artificial Intelligence Excellence Awards programme from Business Intelligence Group.   Shaker was one of six receiving an individual award from Business Intelligence Group, which recognises people and organisations applying… Read More

#News

#Drug discovery #Innovation #Whitepaper

Whitepaper: Maximising outsourcing models beyond time and cost

In this whitepaper, we will expand on key factors – cost, time, and innovation – and illustrate how integrating these factors will minimise the challenges and ensure success in outsourcing drug discovery. Learn about: Opportunities, options, and outsourcing of drug discovery programs Hidden costs vs. hidden value Impact on… Read More

#News

#AI #Drug discovery

Iktos teams up with Ono Pharmaceuticals on AI project  

Artificial intelligence (AI) company Iktos has announced a collaboration with Ono Pharmaceuticals focused on expediting drug discovery for pre-clinical candidates.   The collaboration will see Iktos apply its de novo ligand and structure-based generative modelling technologies and software Makaya to complement Ono’s drug discovery capabilities. More so, Iktos… Read More

#News

#Clinical trial #Drug development #Drug discovery #Therapeutics

Rani Therapeutics initiates Phase I study osteoporosis drug 

Rani Therapeutics, a clinical stage biotherapeutics company focused on the oral delivery of biologics, has initiated a Phase I study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) for the treatment of osteoporosis, delivered via capsule.  The first subject has been administered RT-102… Read More

#News

#Drug discovery #University of Glasgow #University of Southampton

Snail venom could be key to new pain relief medicines

New and more effective forms of pain relief medication could be developed using research based off the deadly venom of poisonous sea snails.   This is according to a team of researchers from the University of Glasgow, which is setting out to learn about the unique form… Read More

#News